For a study, it was determined that certain therapeutic microorganisms, such as Bifidobacteria infantis (B. infantis) 35624, mimic commensal-immune interactions and had favorable immunoregulatory effects. However, the utility of these effects in patients with non-gastrointestinal inflammatory disorders was unknown. The researchers observed the effects of taking B. infantis 35624 orally for 6-8 weeks on inflammatory biomarker and plasma cytokine levels in patients with ulcerative colitis (UC) (n=22), chronic fatigue syndrome (CFS) (n=48), and psoriasis (n=26) in 3 separate randomized, double-blind, placebo-controlled interventions. The impact of B. infantis 35624 on immunological indicators in healthy persons (n=22) was also investigated. Comparable to healthy volunteers, both gastrointestinal (UC) and non-gastrointestinal (CFS and psoriasis) patients exhibited significantly higher plasma levels of C-reactive protein (CRP), as well as the pro-inflammatory cytokines tumor necrosis factor (TNF-α) and interleukin-6 (IL-6). Comparable to placebo, B. infantis 35624 feeding resulted in lower plasma CRP levels in all three inflammatory illnesses. In CFS and psoriasis, plasma TNF α- was lowered, whereas IL-6 was reduced in UC and CFS. Furthermore, after eight weeks of feeding, LPS-stimulated TNF α- and IL-6 release by peripheral blood mononuclear cells (PBMCs) in healthy subjects was significantly reduced in the B. infantis 35624-treated groups compared to placebo. According to the findings, this microorganism can lower systemic pro-inflammatory biomarkers in gastrointestinal and non-gastrointestinal disorders. Finally, it was revealed that the microbiota’s immunomodulatory effects in humans were not restricted to the mucosal immune system, but also extend to the systemic immune system.
Link:www.tandfonline.com/doi/full/10.4161/gmic.25487
